聚（ADP - 核糖）聚合酶1：妇科癌症治疗的希望

Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.

作者信息

Rajawat Jyotika, Shukla Nidhi, Mishra Durga Prasad

机构信息

Cell Death Research Laboratory, Endocrinology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension Lucknow, Uttar Pradesh-226031, India.

Cell Death Research Laboratory, Endocrinology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension Lucknow, Uttar Pradesh-226031, India,

出版信息

Front Biosci (Schol Ed). 2017 Jun 1;9(3):343-356. doi: 10.2741/s491.

DOI:10.2741/s491

PMID:28410123

Abstract

The Poly(ADP-ribose) polymerase-1 (PARP1) is a multifunctional nuclear protein involved in a variety of cellular functions. Recently, its role in the onset, progression and therapy resistance of cancers in general and reproductive cancers in particular has been recognised. The PARP associated signaling is perceived to play a key role in the development, sustenance and relapse of reproductive cancers. This has led to the preclinical and clinical assessment of PARP inhibitors as targeted therapeutic agents in reproductive cancers. In the first part of this review, we have summarized the current status of PARP in the onset, progression and therapy resistance of reproductive cancers. In the second part of the review, we have discussed the translational applications of PARP inhibitors, underscoring the perceived therapeutic opportunities, bottlenecks and the utility of the ongoing clinical trials.

摘要

聚（ADP - 核糖）聚合酶 -1（PARP1）是一种参与多种细胞功能的多功能核蛋白。最近，人们已经认识到它在一般癌症尤其是生殖系统癌症的发生、发展和治疗耐药性中所起的作用。PARP相关信号传导被认为在生殖系统癌症的发展、维持和复发中起关键作用。这促使人们对PARP抑制剂作为生殖系统癌症的靶向治疗药物进行临床前和临床评估。在本综述的第一部分，我们总结了PARP在生殖系统癌症的发生、发展和治疗耐药性方面的现状。在综述的第二部分，我们讨论了PARP抑制剂的转化应用，强调了潜在的治疗机会、瓶颈以及正在进行的临床试验的效用。